ASLAN Gets Global Rights To Almirall RA Candidate, Third Deal In Less Than A Year For Singapore Startup
This article was originally published in PharmAsia News
Executive Summary
ASLAN Pharmaceuticals branches out from oncology for its third compound, but the formula is the same: in-license for Asia and find a CRO.